Ismail Güderer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ismail Güderer has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Sreeparna Banerjee
2 shared publications- Sreeparna Banerjee
Middle East Technical University
2 shared publications - Aliye Ezgi Güleç Taşkıran
Başkent Üniversitesi
1 shared publication - Ariana Noghreh
Department of Biological Sciences, Orta Dogu Teknik Universitesi, Ankara, Turkey
1 shared publication - Aytekin Akyol
Transgenic Animal Technologies Research and Application Center, Hacettepe University, Ankara, Turkey
1 shared publication - Ayşen Yılmaz
Department of Chemistry Middle East Technical University Ankara Türkiye
1 shared publication
Latest Publications
- Open Access
- 26 June 2026
- Published by Wiley in FEBS Letters
Design and analysis strategies for robust microbiome ageing research
The gut microbiome changes systematically with age and associates with age‐related morbidity and mortality, establishing it as a candidate biomarker and intervention target for ageing. Realising this potential requires methodological rigour, as distinguishing genuine biological signals from methodological artefacts remains challenging given variable findings across cohorts. This review provides an integrated framework for human microbiome‐ageing research, organised around five methodological challenges that will collectively strengthen causal inference. We examine how age‐associated factors can correlate with chronological age and may confound the microbiome‐age associations, while selection biases shape old‐age cohorts towards healthier profiles. We address within‐host temporal dynamics and between‐individual heterogeneity that require appropriate sampling to distinguish age‐related signatures from transient states, and validation strategies that separate ageing from batch effects in predictive models. Mendelian randomisation provides causal leverage when triangulated with longitudinal and interventional evidence. Throughout, we examine how design choices determine the limits of analytical inference. The review concludes with a practical checklist, equipping researchers to strengthen reproducibility, improve generalisability and advance microbiome‐based metrics towards validated indicators of biological ageing.
- 26 June 2026
- Published by Wiley in FEBS Letters
Open AccessDesign and analysis strategies for robust microbiome ageing research
The gut microbiome changes systematically with age and associates with age‐related morbidity and mortality, establishing it as a candidate biomarker and intervention target for ageing. Realising this potential requires methodological rigour, as distinguishing genuine biological signals from methodological artefacts remains challenging given variable findings across cohorts. This review provides an integrated framework for human microbiome‐ageing research, organised around five methodological challenges that will collectively strengthen causal inference. We examine how age‐associated factors can correlate with chronological age and may confound the microbiome‐age associations, while selection biases shape old‐age cohorts towards healthier profiles. We address within‐host temporal dynamics and between‐individual heterogeneity that require appropriate sampling to distinguish age‐related signatures from transient states, and validation strategies that separate ageing from batch effects in predictive models. Mendelian randomisation provides causal leverage when triangulated with longitudinal and interventional evidence. Throughout, we examine how design choices determine the limits of analytical inference. The review concludes with a practical checklist, equipping researchers to strengthen reproducibility, improve generalisability and advance microbiome‐based metrics towards validated indicators of biological ageing.
- Open Access
- 22 January 2024
- Published by Elsevier in Translational Oncology
- Vol. 41, 101860
Lysosomal alkalinization in nutrient restricted cancer cells activates cytoskeletal rearrangement to enhance partial epithelial to mesenchymal transition
- 22 January 2024
- Published by Elsevier in Translational Oncology
- Vol. 41, 101860
Open AccessLysosomal alkalinization in nutrient restricted cancer cells activates cytoskeletal rearrangement to enhance partial epithelial to mesenchymal transition
- 25 February 2022
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 27 (3) , 290-300
Development of ACE2 loaded decoy liposomes and their effect on SARS-CoV-2 for Covid-19 treatment
SARS-CoV-2 is a novel coronavirus with a positively oriented single-stranded RNA that first appeared in December 2019. In this study, Angiotensin Converting Enzyme 2 (ACE2) loaded decoy liposomes were developed and characterized. ACE2 protein was loaded onto a liposomal carrier system and its toxicity and effectiveness were evaluated in cell culture and in vitro virus neutralization studies. Liposomes were prepared with the film hydration method and adjusted for size with the dialysis membrane method or the ultrasonic homogenization method. All formulations showed high entrapment efficiency between 99.98–79.6%. Liposomes with two different particle sizes above 2 µm and below 500 nm were obtained with the dialysis membrane method and homogenization method. Two optimum formulations, M6-S90 with a PDI value of 0.383 ± 0.053 and particle size of 397.7 ± 28.25 nm which was produced by ultrasonic homogenization and M6-4 with a PDI 0.769 ± 0.205 and particle size of 2606 ± 1396.00 were chosen as optimum formulations for further studies. M6-S90 was stable and showed low toxicity on Calu3 lung epithelial cells. Pre-incubation of M6-S90 with with 3.1 × 105 PFU/mL of SARS-CoV-2 followed by incubation with Vero E6 cells resulted in a 4 log fold change reduction in cell death compared to virus alone. This suggests that MS6-S90 had good neutralization activity on SARS-CoV-2 whilst maintaining viability of the host cell. The novel ACE-2 loaded decoy liposomes described in this study can be further evaluated for the treatment of COVID-19.
- 25 February 2022
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 27 (3) , 290-300
Development of ACE2 loaded decoy liposomes and their effect on SARS-CoV-2 for Covid-19 treatment
SARS-CoV-2 is a novel coronavirus with a positively oriented single-stranded RNA that first appeared in December 2019. In this study, Angiotensin Converting Enzyme 2 (ACE2) loaded decoy liposomes were developed and characterized. ACE2 protein was loaded onto a liposomal carrier system and its toxicity and effectiveness were evaluated in cell culture and in vitro virus neutralization studies. Liposomes were prepared with the film hydration method and adjusted for size with the dialysis membrane method or the ultrasonic homogenization method. All formulations showed high entrapment efficiency between 99.98–79.6%. Liposomes with two different particle sizes above 2 µm and below 500 nm were obtained with the dialysis membrane method and homogenization method. Two optimum formulations, M6-S90 with a PDI value of 0.383 ± 0.053 and particle size of 397.7 ± 28.25 nm which was produced by ultrasonic homogenization and M6-4 with a PDI 0.769 ± 0.205 and particle size of 2606 ± 1396.00 were chosen as optimum formulations for further studies. M6-S90 was stable and showed low toxicity on Calu3 lung epithelial cells. Pre-incubation of M6-S90 with with 3.1 × 105 PFU/mL of SARS-CoV-2 followed by incubation with Vero E6 cells resulted in a 4 log fold change reduction in cell death compared to virus alone. This suggests that MS6-S90 had good neutralization activity on SARS-CoV-2 whilst maintaining viability of the host cell. The novel ACE-2 loaded decoy liposomes described in this study can be further evaluated for the treatment of COVID-19.
- 1 June 2019
- Published by INIST-CNRS in Atlas of Genetics and Cytogenetics in Oncology and Haematology
- No. 5
PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1)
- 1 June 2019
- Published by INIST-CNRS in Atlas of Genetics and Cytogenetics in Oncology and Haematology
- No. 5
PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1)